| Literature DB >> 3052682 |
E M Grace1, E M Gerecz, Y B Kassam, H M Buchanan, W W Buchanan, P S Tugwell.
Abstract
Fifty-foot walking time was used in 51 of 187 clinical therapeutic trials of antirheumatic drugs and in only 21 instances was statistical significance reached. Measurement of the 50-foot walking time showed no better performance in long-term trials of SAARDs than in short-term trials of NSAIDs. It is concluded that the 50-foot walking time is a poor outcome measure in rheumatic disease trials, despite a high intra- and interobserver reproducibility.Entities:
Mesh：
Year: 1988 PMID： 3052682 DOI： 10.1093/rheumatology/27.5.372
Source DB: PubMed Journal: Br J Rheumatol ISSN： 0263-7103